Kamuvudine-9 (K9) in Diabetic Macular Edema

Part of paid clinical trials in Roanoke, Virginia.

Sponsor
Dr. Bryan Strelow
Study ID
NCT07458061
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Placebo Tablet: BID — DRUG
    Placebo tablets BID
  • Kamuvudine K9 — DRUG
    Kamuvudine K9

Study Details

The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral placebo

Key Dates

Start date
Feb 28, 2026
Status verified
Mar 2026
Primary completion
Jun 30, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo Group 1
    Placebo tablets
  • Experimental: Kamuvudine Group 2
    Kamuvudine tablets BID

Primary Outcome Measure

Number of participants with treatment-related adverse events as assessed by CTCAE v6.0 [ Time Frame: 4 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Vistar Eye CenterRoanokeVirginia24019
Mary Galyen, BS, COA
[email protected]
826-867-8808
Bryan Strelow, MD
[email protected]
540-855-5100
Bryan Strelow, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Roanoke, VA

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
Vistar Eye Center· Roanoke, VA

Related Studies